Study Title: Investigating the safety and anticancer activity of SRT alone in cats with oral squamous cell carcinoma

Purpose of Study: The purpose of this study is to investigate the single-agent anticancer activities of advanced radiation therapy called stereotactic radiotherapy (SRT). This form of radiation allows for precise delivery of high doses of radiation to kill cancer cells within the treatment field. For this study, a total of 5 cats will be actively enrolled. Should you decide to enroll your pet in this clinical trial, your cat will receive 3 doses of radiation therapy three days in a row, followed by the placement of an esophageal feeding tube.

Inclusion Criteria:
- Cats with confirmed (cytology or histopathology) oral squamous cell carcinoma
- Cats must be in good overall condition and have no other serious illness.
- NO treatment with anticancer therapies in the past week (radiation or chemotherapy)

Eligibility Diagnostics:
Prior to study entry, pet owners will be charged an initial consultation fee and be financially responsible and required to have the following diagnostics performed in their cat:
1) Diagnosis of oral squamous cell carcinoma with histopathology or cytology, if not already documented
2) Screening blood work and urinalysis, if not performed within 7 days
3) CT scan of the head

Treatment:
The feline patient will receive SRT radiation therapy for three days in a row. All patients will have an esophageal feeding tube placed following the third treatment. Routine bloodwork will be performed prior to therapy and at regular scheduled reevaluations after the completion of radiation therapy. Antitumor effects will be determined through serial computed tomography scans.

Compensation:
Following enrollment, the trial will cover all costs toward radiation therapy and all associated costs associated with radiation therapy. The trial will also cover the follow up computed tomography, exam fees, bloodwork, remaining radiation costs and hospitalization. Adverse side effect management will remain the financial responsibility of the pet owner.

Contact Information:
Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at (217) 300-6453 or rmoss81@illinois.edu to refer a patient or for any additional information. Referring veterinarian and client calls are welcome.